Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.09p 6.02p 6.16p 6.16p 6.02p 6.16p 387,278 16:35:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 32.06

Vernalis Share Discussion Threads

Showing 3251 to 3275 of 3825 messages
Chat Pages: Latest  141  140  139  138  137  136  135  134  133  132  131  130  Older
DateSubjectAuthorDiscuss
15/2/2017
15:24
£100 million turnover would see me in long term profit.Success for the Cough and cold product range could do this ona five year view.....fact or fantasy?
fhmktg
14/2/2017
16:29
Bought another £7,000 under 30p. Even if this dips on results it is still a good buy at this price. Tuzistra XR has several selling points that make it attractive, all the information is easily available. It is also worth noting that the $3 million payment announced this morning is only the first in a potential $220m of payments due subject to milestones being reached. I would also draw attention to the flu situation in the US this season which means if the sales team in the US have been doing their job properly we should see take up significantly increased compared to the launch season. h##ps://www.cdc.gov/flu/weekly/usmap.htm
romeike
14/2/2017
12:23
I've been researching a number of pharma co's where the share price has fallen considerably recently and once again I'm finding a similar pattern on director emoluments. For a business that turned over roughly £12m last year to see the directors taking out £1.7m in remuneration seems unacceptable to me. Noses in the trough comes to mind. Garland was paid £865K of which £363K was bonus related. All the bonus payments were attributed to company product milestones nothing was realted to anything financial neither was it related to share price performance. There's a total of 8 directors including the non execs for a business with £12m revenue. Woodford and Invesco need to pressure the board to show restraint. I've no doubt there's potential here but it needs to be realised before these kind of awards are given. One question that does seem obvious is what differentiates VER cold medication from the wider range of products already on the market? (I know they do more than cold remedies but these seem to be at the forefront of immediate revenue generation) It's now on my watch list but need to see greater revenue and stricter cost control otherwise there'll end up being a further placing. I await the results with anticipation. woody
woodcutter
14/2/2017
09:55
Only a week to the results and good figures for Tuzistra should set the base for significant turnaround.
fhmktg
14/2/2017
09:35
Great news. And we're below Fridays value?
bantam175
14/2/2017
07:41
RNS today... "Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc Vernalis plc is pleased to announce the achievement of a clinical milestone from its collaboration with Corvus Pharmaceuticals Inc ("Corvus") triggering a payment of $3 million to Vernalis. In February 2015, the Company licensed exclusive, worldwide rights to its adenosine receptor antagonist programme, CPI-444, for use in all therapeutic applications to Corvus, a US-based biotechnology company focused on developing novel immuno-oncology therapies. CPI-444 is a patented small molecule that is now being evaluated in a Phase 1/1b trial in patients with advanced cancers. It is the lead molecule in Corvus' pipeline and is being developed both as a single agent and in combination therapy. The clinical trial utilizes an adaptive design that allows expansion of disease-specific cohorts upon reaching certain pre-defined endpoints. Corvus announced positive data from its Phase 1/1b study in January 2017, having achieved the clinical study protocol criteria for expansion in the cohort of patients with renal cell carcinoma with single agent CPI-444. This study expansion triggers the first clinical milestone payment of $3 million under the licensing agreement. Corvus has stated that, if early findings are confirmed with longer follow up and a larger set of patients in this expanded study, a registration trial could commence by the end of 2017. Corvus was launched through a $33.3 million Series A fundraising in 2014 by the founder and former senior management at Pharmacyclics Inc and it raised a further $74.8 million Series B fundraising in 2015 and $70.7 million via a US IPO in March 2016. The licensing deal has the potential for Vernalis to earn approximately $220 million in milestones from all indications, subject to development, regulatory and sales milestones being achieved. In addition, there are mid-single digit royalties payable if a product reaches the market, with the potential to reach low-double digit royalties in certain circumstances..." Http://uk.advfn.com/stock-market/london/vernalis-VER/share-news/Vernalis-PLC-Achievement-of-a-3m-milestone-paymen/73848407
bountyhunter
10/2/2017
14:06
The news about Suir was part of the reason for the unfortunate fall to 32p. The fact is that Vernalis already had all the product it needed for samples in hand but having a long term solution well ahead of launch this winter would be reassuring. Bad news could send this lower but with the low float the upside here I think is much greater. No reason why this can't go to 70-90p and I don't believe the product is expensive enough to warrant concern on the Trump front. good luck all.
romeike
10/2/2017
11:56
Should have said ' having read'
fhmktg
10/2/2017
11:55
Having areas the local press on the takeover of the Suir site it looks like a local entrepreneur with existing interests in Galway.Says they will be up and running within one month and concentrating on contract manufacture .I wold expect an announcement on Moxatag with the results later this month.That, plus some positive news on Tuzamet sales should give the share price a nudge Northwards.
fhmktg
09/2/2017
10:48
I would suspect that a supply agreement with Vernalis would be an important part of the overall deal. We should find out soon- good news for VER if it comes about!
fhmktg
09/2/2017
10:23
Facilities in Ireland operated by the defunt Suir pharma, who was producing Moxatag, have been taken over by IQ Pharmatek. Does anyone know if this deal means IQ Pharmatek will be producing Moxatag or are they merely taking over the site? h##ps://www.rte.ie/news/2017/0112/844426-iq-pharmatek-clonmel/
romeike
09/2/2017
10:19
There will be absolutely no excuses for bad prescribing levels given the heavy investment in the sales team and the extent of severe flu this past season. Of course upcoming results will only contain information about the start of the season but should be a good indicator regardless. Expecting a climb to at least 70p here if revenue is encouraging. EPS presented in sterling should be helped by USD:GBP fx in our favour.
romeike
07/2/2017
12:00
Well, let us hope the interims out soon will give us an idea how the US sales asre going...........
chrisdgb
06/2/2017
20:29
£6.57 to break even. when will i learn!!!
latifs100
31/1/2017
14:08
Just saying: h##ps://www.cdc.gov/flu/weekly/usmap.htm
romeike
31/1/2017
07:13
FFP Wow your lucky, I need more than that to break even.
barrie16
30/1/2017
17:17
Ho Ho, I am one of the B Biotec boys...£1.12 to see braekeven, had em a lot of years..
ffp
30/1/2017
16:06
Roll on!The details of weekly scrip issues for Tuzistra will be a good indicator of the marketability and pricing for the Tris products.That ten bagger might not be too far away!Dum spiro spero.
fhmktg
30/1/2017
14:11
Vernalis plc (LSE: VER) announces that its unaudited interim results for the six months ended 31 December 2016 will be released on Tuesday, 21 February 2017.
bountyhunter
25/1/2017
13:16
Just a ten bagger will do!
fhmktg
25/1/2017
10:01
'On such things dreams are made'
fhmktg
25/1/2017
09:34
chrisdgb I need an avalanche to get me to the British biotech price
barrie16
25/1/2017
08:29
Drift........no interest?!
chrisdgb
05/1/2017
13:23
Better volume here today, would be nice for this stock to break out of its trading range..!
chrisdgb
29/12/2016
15:51
Anyone know what's happening? Not seen any news to justify todays surge.
bantam175
Chat Pages: Latest  141  140  139  138  137  136  135  134  133  132  131  130  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180816 23:35:16